Menopause Society Practice Exam

These questions are part of the practice quiz. Start practicing

• What are the most common causes of primary ovarian insufficiency (POI)?
• How does regular weight-bearing exercise contribute to osteoporosis prevention?
• What is the typical duration of hormone therapy?
• Which condition should be considered as a differential diagnosis for insomnia in menopausal patients?
• Which choice is NOT listed as a lifestyle factor affecting menopausal symptoms?
• What is the expected duration of the early menopausal transition according to STRAW?
• Which of the following is an absolute contraindication to hormone therapy?
• What are key metabolic concerns in PCOS?
• Which of the following are conservative measures for urinary incontinence?
• How does POI affect fertility?
• What is the prevalence of AUB in perimenopausal women?
• What screening tools are validated for intimate partner violence in midlife women?
• What cognitive changes are reported in midlife women?
• What is the recommended duration of systemic hormone therapy for vasomotor symptoms?
• In POI, HT is used to relieve symptoms and prevent osteoporosis.
• Define arthralgia.
• How is arthralgia related to estrogen decline?
• Which conservative measures are recommended for urinary incontinence?
• Which class of drugs is commonly used to treat osteoporosis?
• Which statement about osteoporosis prevention is true?
• Name two first-line pharmacologic therapies for osteoporosis in postmenopausal women.
• Which statement about frailty is true?
• What is the initial step in evaluating hair loss during menopause?
• Which statement best describes non-hormonal management of vasomotor symptoms?
• What is the FRAX threshold for pharmacologic therapy in terms of 10-year fracture risk?
• Which of the following is a SERM used in menopause management?
• What is an effect of hormone therapy on sexual function in postmenopausal women?
• Hormone therapy in women with POI is recommended for symptom relief and bone protection until approximately what age?
• What hormone pattern is typical in POI?
• What is the role of pelvic floor physical therapy in managing sexual dysfunction in menopause?
• Name two measures of ovarian reserve used in the menopause transition.
• Which statement best describes phytoestrogens in menopause?
• Name one general risk factor for cardiovascular disease in midlife women.
• What symptoms are commonly associated with LOOP events during perimenopause?
• What is pelvic organ prolapse?
• What is the estimated prevalence of menopause among women aged 45-55 years?
• What is the definition of frailty?
• What is the approximate prevalence of depression during the menopause transition?
• What is the role of vaginal moisturizers and lubricants in managing genitourinary syndrome of menopause (GSM)?
• How is abnormal uterine bleeding defined?
• The Basson model is primarily used to understand which domain?
• Which statement best describes dosing for hormone therapy?
• Which are common treatments for menopausal arthralgia?
• Which combination lists correct risk factors for urinary incontinence in midlife women?
• What is the role of progestin in hormone therapy?
• Which of the following is NOT a common side effect of hormone therapy?
• Which of the following is not considered a first-line pharmacologic therapy for osteoporosis?
• What are common components of frailty?
• Which term describes an abnormal luteal phase with altered hormone secretion?
• Which herbal supplement is commonly cited as having insufficient evidence for menopause symptom relief?
• Which of the following is a surgical option for severe pelvic organ prolapse?
• Which statement best describes POI in relation to fertility?
• SERMs are used for which purposes?
• Which hormone therapy is associated with an increased risk of breast cancer?
• How is body mass index (BMI) used in the evaluation of menopausal weight issues?
• What is the impact of androgen decline on sexual function in menopausal women?
• Which statement about pelvic organ prolapse is incorrect?
• Which two conditions are risk factors for sleep changes in menopausal women?
• Which two types of urinary incontinence are commonly recognized?
• What is the role of pelvic floor physical therapy in genitourinary syndrome of menopause?
• In the PALM-COEIN framework, adenomyosis is categorized as which type of etiology?
• Which immunizations are recommended for midlife women to reduce morbidity?
• Which hormonal change is associated with the menopause transition?
• Which statement best describes the role of menopausal hormone therapy in cardiovascular disease prevention?
• Name a surgical option for refractory AUB.
• What is the recommended role for hormone therapy in women with POI?
• Which statement best describes VMS prevalence and duration?
• Which physical examination findings are important when evaluating abnormal uterine bleeding (AUB)?
• Which statement best describes patient education for menopause?
• Which factor influences the cardiovascular risk associated with hormone therapy?
• What is surgical menopause?
• Which intervention is described as first-line for metabolic abnormalities in PCOS?
• The Basson model is a model of which aspect relevant to menopause?
• GSM is most directly caused by what deficiency?
• What marks the postmenopausal period?
• Name three risk factors for AUB in midlife women.
• What lifestyle factors affect menopausal symptoms?
• Which drug class includes alendronate, risedronate, and zoledronic acid?
• Which of the following is a risk factor for depression during menopause?
• What T-score defines osteoporosis?
• Which statement is true about Orlistat as a weight-loss therapy for postmenopausal women?
• What is the evidence for the efficacy of over-the-counter herbal supplements in menopause symptom relief?
• Which statement best describes non-pharmacological interventions for vasomotor symptoms?
• Which statement about hair loss patterns observed in menopause is accurate?
• Which symptom prompts evaluation for endometrial hyperplasia or cancer?
• Which combination is used in hormone therapy for menopausal symptoms?
• What is the evidence for compounded bioidentical hormones?
• Which of the following is a nonhormonal prescription option for vasomotor symptoms (example: SNRI)?
• Local estrogen therapy is especially helpful for which symptom cluster in menopause?
• Which pharmacologic option is a non-hormonal choice for vasomotor symptoms?
• What is the impact of menopause on quality of life?
• Which sites are most commonly affected by osteoporotic fractures?
• What is the role of selective estrogen receptor modulators (SERMs)?
• What is the most common cardiovascular disease in postmenopausal women?
• A T-score of -3.0 indicates which bone health condition?
• Name two local therapies for GSM.
• Which of the following is a nonhormonal prescription option for vasomotor symptoms?
• Which of the following is a surgical option for weight loss in menopausal women with obesity?
• After menopause, which lipid parameter tends to decrease?
• Which estrogen delivery method is associated with a lower risk of venous thromboembolism and stroke?
• Which of the following is a common side effect of systemic hormone therapy?
• Abnormal uterine bleeding in peri/menopause may be a sign of what?
• What is a potential health outcome of untreated sleep disturbance in menopause?
• What is the effect of hormone therapy on bone?
• Tibolone is best described as what kind of agent?
• Which of the following is a structural cause of AUB?
• What dietary pattern supports bone health in postmenopausal women?
• Frailty risk in midlife increases with aging and deficiency of which hormone?
• Are compounded bioidentical hormones FDA-approved and standardized in dosing?
• Which statement best describes recommended patient education for menopause?
• Why is progestogen added to estrogen therapy in women who have an intact uterus?
• Which classification system is used for AUB etiologies?
• Which of the following is NOT a commonly described component of frailty?
• Which of the following is an iatrogenic cause of POI?
• Which of the following is NOT a barrier to care?
• What is the initial step in evaluating AUB?
• Which local therapy is recommended for genitourinary syndrome of menopause?
• What are common factors contributing to weight gain during menopause?
• Which of the following are risk factors for urinary incontinence in midlife women?
• What is the primary effect of menopause on bone health?
• What is the recommended method for assessing central adiposity in cardiovascular risk assessment?
• Which cancers have screening recommendations relevant to menopausal women?
• Pelvic floor physical therapy in GSM has been shown to do what?
• What is the gold standard test to diagnose osteoporosis?
• What lifestyle measures help prevent osteoporosis?
• Which statement about hypertension risk after menopause is true?
• How does the menopause transition differ from postmenopause in terms of hormonal changes?
• Which option is NOT a recommended focus of menopause education?
• What is the first-line treatment for mild pelvic organ prolapse?
• Sacrocolpopexy is a surgical option for which condition?
• Premature ovarian insufficiency is defined as ovarian failure before what age?
• Which of the following is NOT a barrier to care for menopausal women?
• List two non-structural causes of AUB.
• Hormone therapy that combines estrogen with progestin has been linked to increased risk of which condition?
• Arthralgia during menopause is most closely associated with which hormonal change?
• Which of the following is NOT a barrier to care for menopausal women?
• Which is a key goal of menopause patient education?
• Which of the following is NOT a STRAW+10 phase?
• Which of the following are common symptoms of pelvic organ prolapse?
• Which STRAW stage is characterized by variable cycle length and increased FSH?
• List three causes of secondary amenorrhea in women under 40.
• What is a surgical option for weight loss in menopausal women with obesity?
• Which two non-pharmacologic strategies are cited for managing vasomotor symptoms?
• In STRAW+10, postmenopause refers to which time period?
• Name one primary prevention strategy for cardiovascular disease in midlife women.
• Name one nonhormonal pharmacologic therapy for VMS.
• In sequential therapy, progestogen is taken for how many days per month typically?
• Which statement about first-line medical therapy for AUB is correct?
• Which statement best describes STRAW+10 staging system?
• Which is a behavioral therapy for sleep changes in menopause?
• What is the term for the interval of hormonal fluctuation and menstrual irregularity before menopause?
• Endometrial biopsy in AUB is indicated in which scenario?
• What is the first-line lifestyle intervention for weight management in menopause?
• Which statement correctly describes a key difference between continuous and sequential hormone therapy regimens?
• What is the definition of hormone therapy (HT)?
• Name three common sexually transmitted infections relevant to midlife women.
• What is the mean age of natural menopause in the United States?
• Which pharmacologic agent is preferred for women at very high risk of fracture?
• Which option is NOT a common cause of POI?
• What are the benefits of weight-bearing exercise?
• Which statement is true about GSM treatment?
• How does the prevalence of hypertension change after menopause?
• Which symptom is commonly associated with perimenopause?
• What is the effect of smoking on menopause?
• Which imaging modality is not considered first-line for evaluating abnormal uterine bleeding?
• Which of the following is a risk factor for depression in midlife women during menopause?
• Which option is NOT a barrier to care for menopausal women?
• Which drug is an anabolic agent used in osteoporosis management?
• Which item should be included in patient education about menopause?
• Which of the following is a non-structural cause of AUB?
• PCOS is associated with increased risk of which cardiovascular/metabolic conditions?
• Name two clinical consequences of early estrogen loss.
• Which of the following are potential risks of surgical menopause?
• How does menopause affect bone density?
• What is the role of hormone therapy in the prevention of postmenopausal osteoporosis?
• Which screening test is recommended for thyroid disease in symptomatic or high-risk midlife women?
• In evaluating menopausal sleep changes, which intervention is categorized as a behavioral therapy?
• What is the risk of venous thromboembolism with hormone therapy?
• Which statement is true about sleep disturbances and menopause?
• What is the prevalence of arthralgia during the menopause transition?
• Which condition is a differential diagnosis for insomnia in menopause?
• What laboratory test is essential in all women presenting with abnormal uterine bleeding?
• What is the recommended vitamin D intake?
• Name a first-line medical therapy for AUB.
• Define a luteal out-of-phase (LOOP) event and its clinical significance.
• Which statement best describes the overall impact of menopause on cardiovascular risk?
• What percentage of midlife women experience arthralgia during the menopause transition?
• Name one medication class used to treat osteoporosis.
• What are the dominant symptoms during the late menopausal transition?
• Which joints are commonly affected by arthralgia in menopausal women?
• What is the prevalence of sexual dysfunction in postmenopausal women?
• Polycystic ovary syndrome is best described as which combination?
• In midlife women with PCOS, which features are commonly present?
• How does estrogen deficiency contribute to hair changes in menopause?
• What is the recommended screening interval for mammography in women aged 50-74?
• What is bioidentical hormone therapy?
• What is the risk of cardiovascular disease in POI?
• Which of the following is a risk factor for pelvic organ prolapse?
• What is the recommended calcium intake for postmenopausal women?
• Which hormonal changes during menopause are associated with reduced libido, arousal, and vaginal lubrication?
• What is the clinical definition of menopause?
• What is the definition of surgical menopause?
• What is the first-line imaging modality for evaluating AUB?
• In the PALM-COEIN framework, which is a structural etiology?
• Local estrogen therapy may improve which menopausal symptoms?
• Which of the following is NOT a barrier to care?
• Which statement correctly describes the PALM-COEIN framework?
• In hair loss evaluation during menopause, which component is considered an initial step?
• Approximately what percentage of women experience VMS during menopause?
• For postmenopausal bone health, what is the recommended combination of calcium and vitamin D?
• Which statement about route of estrogen therapy and thrombosis risk is accurate?
• How does a decline in estrogen affect bone health during menopause?
• What is the role of hormone therapy in POI?
• Which non-pharmacologic strategy is recommended for menopausal hair loss?
• What is genitourinary syndrome of menopause (GSM)?
• What is tibolone and in what context is it used?
• According to WHO criteria, osteoporosis is defined by a T-score ≤ -2.5 at which sites?
• Which two cancer treatments can induce menopause?
• Between which ages is menopause most likely to occur?
• What is the effect of hormone therapy on cardiovascular disease risk?
• Name three major risk factors for low bone mass and fracture in postmenopausal women.
• Urinary incontinence is defined as what?
• Name one first-line treatment for metabolic abnormalities in PCOS.
• List two structural causes of AUB.
• HT in POI is recommended until the average age of menopause.
• What are risks of surgical menopause?
• Which of the following is NOT a barrier to care for menopausal women?
• What symptoms define vasomotor symptoms (VMS)?
• Name one FDA-approved pharmacologic therapy for weight loss in postmenopausal women.
• Which factor is NOT commonly associated with weight gain during menopause?
• A comprehensive menopause education plan should cover which of the following?
• Which of the following is a non-pharmacologic approach to managing menopausal symptoms?
• Which sites are used to assess BMD for osteoporosis diagnosis per WHO criteria?
• What is the recommended daily intake of calcium and vitamin D for postmenopausal women?
• Which statement about GSM local therapies is true?
• What is the first-line therapy for moderate to severe VMS?
• How is osteoporosis defined?
• What are treatment goals in POI?
• Which statement best describes the risks of compounded or non-approved hormone therapy preparations?
• What does FRAX combine to estimate 10-year fracture risk?
• Which statement about pelvic organ prolapse risk factors is true?
• Which of the following is a key metabolic concern in PCOS?
• Which combination of vaccines is recommended for midlife women to reduce morbidity?
• Systemic hormone therapy should be reassessed annually.
• Which topics are appropriate to include in menopause patient education?
• Which option is NOT a barrier to care?
• PCOS is associated with increased risk of which cardiovascular/metabolic conditions?
• Which statement about GSM?
• Which pair represents SERMs used in menopause management?
• Which STRAW stage follows the reproductive phase?
• What is the most common sleep disturbance in menopause?
• What is the preferred route of estrogen therapy to reduce thrombosis risk?
• Which vaccine reduces the risk of cervical cancer?
• Which statement is true about vaginal estrogen for GSM?
• Osteopenia is defined by what T-score range on DXA?
• What is the role of cognitive behavioral therapy (CBT) in menopause?
• What is the relationship between menopause and sleep apnea?
• Which tool is commonly used to estimate 10-year fracture risk in clinical practice?
• Endometrial biopsy is indicated in AUB for which scenario?
• Which are common side effects of hormone therapy?
• Which topical option is used for androgenic alopecia in postmenopausal women?
• Which of the following is NOT a barrier to care for menopausal women?
• Name two types of hair loss seen in menopausal women.
• What lipid pattern is typically seen after menopause?
• In terms of dietary strategies for bone health, which combination is recommended?
• What is the age threshold for routine DXA screening in postmenopausal women, according to the North American Menopause Society?
• Are these cognitive changes associated with menopause hormone levels?
• Which of the following is an example of a nonhormonal pharmacologic therapy for VMS?
• List the three main phases defined by the STRAW+10 staging system.
• What is the median duration of VMS?